Posted inInfectious Diseases news Pediatrics
EuTCV Vi‑CRM197 (Single‑ and Multidose) Is Non‑Inferior to Typbar TCV in Infants and Well Tolerated Across Age Groups in Kenya and Senegal
A multicentre phase 3 trial shows single‑ and multidose EuTCV (Vi‑CRM197) are immunologically non‑inferior to Typbar TCV in infants 9–12 months, with comparable safety and reactogenicity across ages — supporting WHO prequalification.